Three Themes You'll Take Away From "Health Spending: Moving From Theory to Action"
(9/4, National Pharmaceutical Council: E.V.I.dently Today) comments “...The conference will force attendees to confront the reality of tradeoffs to efficiently address the unsustainable rate of health spending in the United States. What is society willing to pay? What must be left out? Under which circumstances can health spending be cost-effective and lead to improved health outcomes?...The event builds on a multi-year effort launched 18 months ago at a standing-room only conference by Health Affairs and NPC to promote an evidence-based conversation about health spending. The project explores questions involving the level and growth rate of health spending, the distribution of spending, efforts to improve the value of care, and analysis of options for constraining health care costs.” Full
Releasing the Potential of Real World Evidence
(9/4, Janssen, PharmaTimes) comments “...RWE can help to shape clinical development plans and early drug discovery, optimise patient recruitment for RCTs and identify new areas of research. It can help us better understand disease and treatment pathways, assess the safety and effectiveness of newly-launched drugs, as used in the real world, and – ultimately – it will also be impactful on clinical practice and outcomes for patients. The key to releasing the full potential of RWE is collaboration. If we can find ways of working together at scale; if data sharing across Europe – and the world – is incentivised, there's a huge opportunity for RWE to help realise an efficient, personalised and truly patient-centric healthcare system.” Full
Putting The Costs And Benefits Of New Gene Therapies Into Perspective
(9/4, Joshua T. Cohen, et al., Health Affairs Blog) comments “...One option for addressing uncertainty pertaining to long-term effectiveness is to use the most conservative assumption about the therapy's effectiveness durability, as documented by empirical data from randomized clinical trials. But such an assumption can be scientifically implausible (that the treatment effect ends after a trial's termination) and could risk substantially understating the value of therapies. Placing too low a price on these therapies could, in turn, lead to under-investment in innovation. The most reasonable course is to use post-approval data collection and risk-sharing arrangements to secure appropriate pricing.” Full
The ‘Evidence-Based Medicine Movement' – Where To, Next?
(9/3, Neil Chanchlani, CMAJ Blog) comments “...EBM is not always about conducting new research to answer novel questions; it can be about identifying poorly conducted research. We must acknowledge that some research practice is poor, be transparent about biases, and demonstrate honesty about the limitations of study conduct in interpreting results, says Sir Terence Stephenson, professor of child health at UCL Great Ormond Street Institute of Child Health. He suggested that rewarding peer review, improving resources for tracking patients through observational studies and trials, and blockchain technology are all possible solutions to reducing questionable research practices.” Full
Video: Michael Thompson on Employers Engaging on Value-Based Reimbursement
(9/4, The American Journal of Managed Care) “Currently, employers choose health plans based on administrative costs and provider discounts, but they need to start engaging around value-based reimbursement, said Michael Thompson, president and chief executive officer of the National Alliance of Healthcare Purchaser Coalitions.” View Video
CMS Pushes Back ACO Notification Requirement, ACOs Want It Struck
(9/3, Chelsea Cirruzzo, InsideHealthPolicy.com) reports “...ACOs won't be penalized for failing to provide beneficiaries with written notification that they are assigned to an ACO prior to or at their first primary care visit of the performance year, according to an email CMS sent to providers Wednesday. The requirement to provide standardized written notices began on July 1 as part of CMS' ACO overhaul.” Paid Subscription Required
UK: Amid Zolgensma Crisis, Novartis Gets a Gene Therapy Boost as NICE Embraces Luxturna
(9/4, Angus Liu, Fierce Pharma) reports “...At its list price of £613,410 ($745,650) per patient, the drug would have failed the Budget Impact Test, meaning it would have cost the public health system too much, NICE said. However, like almost all other drugmakers do to win NICE backing, Novartis has offered NHS England a confidential discount. ‘This latest deal reinforces the benefits for companies willing to engage with us and be pragmatic with their pricing—which is good news for patients, tax payers and industry,’ NHS chief executive Simon Stevens said in a statement.” Full
UA Awarded $1.4M Grant for Program that Supports Sleep Apnea Patients
(9/3, The University of Arizona Health Sciences Press Release) “University of Arizona College of Medicine – Tucson Professor Sairam Parthasarathy, MD, has been awarded nearly $1.4 million for a peer-support program for sleep apnea patients. The funding — from the Patient-Centered Outcomes Research Institute — will be used by Dr. Parthasarathy and his research team to implement the findings of a previous research project in which peers were trained to help patients starting treatment for sleep apnea.” Full
UC Davis Health and NEC Society Partner to Help Premature Infants, Families
(9/3, UC Davis Health Press Release) “The NEC Society, an organization that aims to eliminate necrotizing enterocolitis, received $250,000 from the Patient-Centered Outcomes Research Institute to build its research capacity. The organization will partner with UC Davis Health's Center for Healthcare Policy and Research to achieve key goals in its two-year project.The PCORI award will advance the NEC Society's ability to drive research and serve as a model for others studying rare neonatal diseases.” Full
Challenges in Assessing the Clinical Utility and Economic Value of Immune Checkpoint Inhibitor Therapies of Cancer
Peter Paul Yu, et al.
September 3, 2019, Journal for ImmunoTherapy of Cancer
Reminder: Health Spending: Moving From Theory to Action
September 11, 2019
National Press Club